Literature DB >> 18226500

Adjunctive psychosocial therapies for the treatment of schizophrenia.

Thomas L Patterson1, Oscar R Leeuwenkamp.   

Abstract

Antipsychotic pharmacotherapy is the standard of care for the treatment of schizophrenia. Although pharmacotherapy effectively improves some symptoms, others can remain. Pharmacotherapy alone also tends to produce only limited improvement in social functioning and quality of life. Supportive psychosocial therapies have been used as adjuncts to pharmacotherapy to help alleviate residual symptoms and to improve social functioning and quality of life. Additionally, therapies with psychoeducational components can focus on improving medication adherence and reducing relapse and rehospitalization. This review describes the major psychosocial therapeutic strategies that have been used effectively in patients with schizophrenia (cognitive-behavioral therapy, family intervention, social skills, and cognitive remediation), with emphasis on their utility in improving medication adherence. Therapies that integrate various psychosocial therapeutic approaches are also discussed. It is concluded that psychosocial therapy is an effective adjunct to pharmacotherapy for schizophrenia. However, these therapies vary significantly in the functional domains that they address. It is therefore important to identify the form of psychosocial intervention most likely to benefit the individual patient, and to recognize that the effectiveness of any psychosocial intervention could be influenced by such factors as the presence and severity of psychotic or affective symptoms or cognitive impairment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18226500     DOI: 10.1016/j.schres.2007.12.468

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  16 in total

Review 1.  Elderly patients with schizophrenia and depression: diagnosis and treatment.

Authors:  Kandi Felmet; Sidney Zisook; John W Kasckow
Journal:  Clin Schizophr Relat Psychoses       Date:  2011-01

2.  Conceptualization and treatment of negative symptoms in schizophrenia.

Authors:  Sonali Sarkar; Kiley Hillner; Dawn I Velligan
Journal:  World J Psychiatry       Date:  2015-12-22

3.  Feasibility and usefulness of training assertive community treatment team in cognitive behavioral therapy.

Authors:  Narsimha R Pinninti; Jillian Fisher; Kelly Thompson; Robert Steer
Journal:  Community Ment Health J       Date:  2009-12-02

4.  Comprehensive early intervention for patients with first-episode psychosis in Japan (J-CAP): study protocol for a randomised controlled trial.

Authors:  Shinsuke Koike; Atsushi Nishida; Syudo Yamasaki; Kayo Ichihashi; Sanae Maegawa; Tatsunobu Natsubori; Hirohiko Harima; Kiyoto Kasai; Izumi Fujita; Masanori Harada; Yuji Okazaki
Journal:  Trials       Date:  2011-06-20       Impact factor: 2.279

5.  Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia.

Authors:  Pudtan Phanthunane; Theo Vos; Harvey Whiteford; Melanie Bertram
Journal:  Cost Eff Resour Alloc       Date:  2011-05-13

6.  Recovery from schizophrenia: a four-year study of an inner city cohort.

Authors:  Marina Economou; Alexandra Palli; Lily Peppou; Michael Madianos
Journal:  Community Ment Health J       Date:  2011-02-22

7.  The Six-Point Dial of Treatment: A Useful Framework for Novice Therapists.

Authors:  Tracy K Witte; Kathryn H Gordon; Thomas E Joiner
Journal:  Clin Case Stud       Date:  2009-06-01

8.  Dorsolateral prefrontal cortex activity predicts responsiveness to cognitive-behavioral therapy in schizophrenia.

Authors:  Veena Kumari; Emmanuelle R Peters; Dominic Fannon; Elena Antonova; Preethi Premkumar; Anantha P Anilkumar; Steven C R Williams; Elizabeth Kuipers
Journal:  Biol Psychiatry       Date:  2009-06-27       Impact factor: 13.382

Review 9.  Emerging therapeutic targets for schizophrenia: a framework for novel treatment strategies for psychosis.

Authors:  Susan F Sonnenschein; A Grace
Journal:  Expert Opin Ther Targets       Date:  2020-11-26       Impact factor: 6.902

10.  Reward learning as a potential target for pharmacological augmentation of cognitive remediation for schizophrenia: a roadmap for preclinical development.

Authors:  Dean T Acheson; Elizabeth W Twamley; Jared W Young
Journal:  Front Neurosci       Date:  2013-06-18       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.